Medicine
Fabior 0.1% foam
Fabior 0.1% foam is a prescription medicine containing Tazarotene for topical use, marketed by Mayne Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Protect from freezing. Store at 20°C to 25°C (68°F to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Tazarotene
- Brand
- Fabior
- Strength
- 0.1%
- Dosage form
- Foam
- Route
- Topical
- Packs
- 1 can
- Marketing authorisation holder
- Mayne Pharma
- Manufacturer
- Mayne Pharma
- Origin register
- US FDA, United States
- Storage
- Protect from freezing. Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). See USP-controlled room temperature. Do not expose to heat or store at temperatures above 120°F (49°C). Store upright.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D05AX05 Tazarotene
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 March 2017
- Identifiers
- RxCUI 1293451, 1293456DailyMed set ID ae0afed7-1d60-45fd-a08b-8db094618521NDC 51862-295Application NDA202428
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 can in 1 carton / 100 g in 1 can | 51862-295-10 | Mayne Pharma | 17 March 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 13 June 1997 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Tazarotene 0.1% foam.
Other strengths and forms of Tazarotene
Clinical summary
Tazarotene is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement, among other approved uses. It is available as gel, cream and foam for topical and cutaneous use. MedsAcross supplies Tazarotene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TazaroteneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Tazorac prescribing information (Almirall) · U.S. National Library of Medicine, DailyMed
Need Fabior 0.1% foam for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.